EpiCast Report : Acne, Overweight and Obesity And Chronic Kidney Disease Epidemiology Forecast to 2022
Restored from the Empower Network archive (2011–2017), lightly edited to meet our current advertising standards. Views are the original author’s.
Researchmoz presents this most up-to-date research on”EpiCast Report : Acne, Overweight and Obesity And Chronic Kidney Disease Epidemiology Forecast to 2022″.The report focuses primarily on quantitative market metrics in order to characterize the growth and evolution of the Remote Patient Monitoring Market.
EpiCast Report : Acne Epidemiology Forecast to 2022
( )
Acne vulgaris (acne) is an inflammatory skin disease that affects nearly all adolescents and adults at some point in their lives. The clinical presentation of acne ranges from a mild comedonal form to severe inflammatory cystic acne of the face, chest, and back. Globally, acne has a lifetime prevalence of over 90% in people of all ages, and a point-prevalence of approximately 85% in the population ages 15–24 years.
Epidemiological analysis forecasts an increase in the total prevalent cases of acne in people ages 10–44 years in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK), from 103.91 million prevalent cases in 2012 to 105.46 million prevalent cases in 2022, with a decadal growth rate of 1.5%. As GlobalData epidemiologists used steady prevalence proportions of acne over the forecast period, the growth in prevalent cases in each market can be attributed to the change in population demographics in people ages 10–44 years in the respective markets.
Although acne is not a life-endangering condition, it is associated with a huge psychosocial impact and economic burden. Epidemiological forecast emphasizes the need for preventive measures that are directed towards high-risk groups and signifies the need for early intervention with the available effective treatments in order to tackle the increasing burden of acne.
Epidemiologists forecast the prevalent cases of acne in the 6MM from 2012–2022 using nationally-representative, country-specific studies published in peer-reviewed journals that provided the ageand sex-specific prevalence of acne in the 6MM. Additionally, they further segmented the total prevalent cases of acne by severity. GlobalData epidemiologists ensured that the forecast methodology was consistent across all the 6MM to allow for a meaningful comparison of the total prevalent cases of acne across these markets.
Scope
The Acne EpiCast Report provides an overview of the risk factors and global trends of acne in the 6MM (US, France, Germany, Italy, Spain, and UK). It includes a 10-year epidemiology forecast of acne prevalent cases segmented by age (in five-year increments beginning at age 0 and ending at age 44 years), sex, and stage in these six markets.
The acne epidemiology report is written and developed by Mastersand PhD-level epidemiologists.
The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 6MM.
EpiCast Report : Overweight and Obesity Epidemiology Forecast to 2022
( )
Overweight and obesity are characterized by abnormal or excessive fat accumulation in the body, which can increase the likelihood of developing type 2 diabetes and cardiovascular diseases. Obesity is an escalating public health problem with an increasing worldwide prevalence and has become a well-known threat to public health. As obesity is a complex condition associated with a wide range of lifestyle, genetic, social, cultural, and environmental factors, its prevalence may vary across countries, depending on the variations in these contributing factors.
GlobalDatas epidemiological analysis forecasts that prevalent cases of overweight in the 9MM (US, France, Germany, Italy, Spain, UK, Japan, Brazil, and Canada) will increase from 250.05 million in 2012 to 271.86 million cases in 2022 at an annual growth rate (AGR) of 0.86%. Approximately 57% of the 250.05 million prevalent cases of overweight adults in the 9MM in 2012 were in men. GlobalData epidemiologists forecast that there were 167.39 million prevalent cases of obesity in the 9MM in 2012, which will increase to 213.34 million cases in 2022, increasing at an AGR of 2.75%. Approximately 52% of the 167.39 million prevalent cases of obese adults in the 9MM in 2012 were in women.
According to GlobalDatas forecast, the prevalent cases of both overweight and obesity will increase dramatically over the next decade, with the number of obese adults increasing by an alarming 27.50%. Overweight and obesity have reached pandemic proportions; however, GlobalData epidemiologists believe that with the alarming increase in the prevalence of both overweight and obesity, the morbidity and mortality associated with the disease will continue to increase dramatically as well.
Scope
The Overweight and Obesity EpiCast Report provides an overview of the risk factors, comorbidities, and global trends of overweight and obesity in the 9MM (US, France, Germany, Italy, Spain, UK, Japan, Brazil, and Canada). It includes a 10-year epidemiology forecast of the prevalent cases of overweight, obesity, obesity class I, obesity class II, and obesity class III segmented by sex and age. In addition, the report includes a 10-year forecast of the prevalent cases of obesity-associated comorbidities, including diagnosed diabetes, diagnosed hypertension, and dyslipidemia, among adults with overweight/obesity in some of these markets.
The overweight and obesity epidemiology report is written and developed by Mastersand PhD-level epidemiologists.
The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 9MM.
EpiCast Report : Chronic Kidney DiseaseEpidemiology Forecast to 2022
()
Chronic kidney disease (CKD), or chronic renal disease, is an asymptomatic, long-term condition that damages the kidneys and leads to the loss of kidney function over time. CKD affects people of all ages; however, the risk is higher in people ages 65 years and older. Globally, the estimated prevalence of CKD is 7.2% in adults over the age of 30 years. The disease is more common in women than men, and is also more common in people of African and South Asian origin due to the high prevalence of diabetes in South Asians and hypertension in people of African origin. Based on the glomerular filtration rate, the Kidney Disease Outcomes Quality Initiative (KDOQI) classified CKD into five stages in 2002. Each stage of CKD requires different tests and treatments for management of the disease.
This report provides an overview of the risk factors and the global and historical trends for CKD in the 6MM. In addition, the report includes a 10-year epidemiological forecast (20122022) of the prevalent cases of CKD segmented by sex, age (in five-year increments beginning at age 20 and ending at age =85 years), and stage in these markets.
Epidemiological forecast is supported by data from country-specific studies published in peer-reviewed journals. GlobalData epidemiologists obtained ageand sex-specific prevalence data for CKD in the 6MM from nationally-representative studies in each country to forecast the total prevalent cases of CKD during the forecast period (20122022).
A major strength of this analysis is the use of country-specific data and a uniform methodology across all the markets to forecast the prevalent cases of CKD. In addition, GlobalData epidemiologists provide segmentation of the CKD prevalent cases by stage per the KDOQI guidelines in each market, despite the stage-specific data being limited to certain age groups and stages.
Scope
The Chronic Kidney Disease EpiCast report provides an overview of the risk factors and global trends of chronic kidney disease in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK). It includes a 10-year epidemiological forecast (20122022) of the prevalent cases of chronic kidney disease segmented by age (in five-year increments beginning at age 20 and ending at age =85 years), sex, and stage (15) in the 6MM
The chronic kidney disease epidemiology report is written and developed by Mastersand PhD-level epidemiologists
In-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 6MM.
About Us:
ResearchMoz () is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
For More Information Kindly Contact:
Mrs.Sheela AK
Tel:+1-518-618-1030
Toll Free: 866-997-4948
State Tower
90 State Street, Suite 700
Albany, NY 12207
United States
Email: sales@researchmoz.us
Blog: